Prostaglandina

Tafluprost CAS 209860-87-7

Obter um orçamento

Última mensagem

Exposto: Os únicos 5 fabricantes chineses de retatrutida que efetivamente enviam para os EUA

2025-12-04

Tesofensina CAS 195875-84-4 | Ingrediente farmacêutico ativo e intermediário | Ningbo Kilo Biotechnology Co., Ltd.

Encomendar Tesofensine a granel sem mínimos: 3 fornecedores que quebram as regras de MOQ!

2025-11-17

Choques de preços da Tesofensina a granel: O que 12 laboratórios realmente pagam (Exposto!)

2025-11-17

Tabela de doses de retatrutida surpreendentemente simples para uma perda de peso de 17% em 6 meses!

2025-11-17

Compreender a dosagem de retatrutida: O que a investigação científica revela sobre o controlo de peso

2025-11-17

Hacks de seguros: Reduzir os custos do Retatrutide em 80% com ESTA estratégia de dosagem

2025-11-17

Tafluprost CAS 209860-87-7

Tafluprost
209860-87-7

Prostaglandina e intermediário

Embalagem de 1kg/saco a 25kg/tambor conforme o pedido.

Modificação de moléculas a pedido (escala de gramas a quilos).

Nome do produto

Tafluprost

N.º CAS.

209860-87-7

Pureza

NLT 99.0%

Embalagem

Embalagem de 1kg/saco a 25kg/tambor conforme o pedido.

Fórmula molecular

C25H34F2O5

Peso molecular

452.5

SORRISOS

CC(C)OC(=O)CCC/C=C\C[C@H]1[C@H](C[C@H]([C@@H]1/C=C/C(COC2=CC=CC=C2)(F)F)O)O

Nome IUPAC

propan-2-yl (Z)-7-[(1R,2R,3R,5S)-2-[(E)-3,3-difluoro-4-phenoxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate

Sinónimo

Tafluprost; 209860-87-7; Taflotan; Zioptan; AFP-168; Saflutan; MK-2452; 1O6WQ6T7G3; CHEBI:66899; DTXSID401021504; MK2452; propan-2-il (5Z)-7-[(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-fenoxibut-1-en-1-il]-3,5-di-hidroxiciclopentil]hept-5-enoato; tafluprostum; tafluprost oftálmico; Ácido 5-heptenóico, éster 7-[(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-fenoxi-1-buten-1-il]-3,5-di-hidroxiciclopentil]-, 1-metiletilo, (5Z)-; (5Z)-7-((1R,2R,3R,5S)-2-((1E)-3,3-DIFLUORO-4-FENOXIBUT-1-ENIL)-3,5-DI-HIDROXICICLOPENTILO)HEPT-5-ENOATO DE ISOPROPILO; (5Z)-7-{(1R,2R,3R,5S)-2-((1E)-3,3-difluoro-4-fenoxibut-1-enil)-3,5-di-hidroxiciclopentilo}hept-5-enoato de isopropilo propan-2-yl (5Z)-7-((1R,2R,3R,5S)-2-((1E)-3,3-difluoro-4-phenoxybut-1-en-1-yl)-3,5-dihydroxycyclopentyl)hept-5-enoate; (Z)-7-((1R,2R,3R,5S)-2-((E)-3,3-difluoro-4-(fenoxi)but-1-enil)-3,5-di-hidroxiciclopentil)hept-5-enoato de propan-2-ilo propan-2-il (Z)-7-[(1R,2R,3R,5S)-2-[(E)-3,3-difluoro-4-(fenoxi)but-1-enil]-3,5-dihidroxiciclopentil]hept-5-enoato; Tafluprost Ophthalmic; RefChem:57842; S01EE05; DTXCID601506522; éster 1-metiletil do ácido 5-heptenóico, 7-((1R,2R,3R,5S)-2-((1E)-3,3-difluoro-4-fenoxi-1-buten-1-il)-3,5-di-hidroxiciclopentilo)-, (5Z)-; 1-methylethyl (5Z)-7-((1R,2R, 3R,5S)-2-((1E)-3,3-difluoro-4-phenoxy-1-butenyl)-3,5-dihydroxycyclopentyl)-5-heptenoate; C25H34F2O5; MFCD08062150; (Z)-isopropyl 7-((1R,2R,3R,5S)-2-((E)-3,3-difluoro-4-phenoxybut-1-en-1-yl)-3,5-dihydroxycyclopentyl)hept-5-enoate; Tapros; isopropyl (5Z)-7-{(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-phenoxybut-1-en-1-yl]-3,5-dihydroxycyclopentyl}hept-5-enoate; isopropyl (Z)-7-[(1R,2R,3R,5S)-2-[(E)-3,3-difluoro-4-phenoxy-but-1-enyl]-3,5-dihydroxy-cyclopentyl]hept-5-enoate; propan-2-il (Z)-7-[(1R,2R,3R,5S)-2-[(E)-3,3-difluoro-4-fenoxibut-1-enil]-3,5-dihidroxiciclopentil]hept-5-enoato; Zioptan (TN); Tafluprost?; AFP-168;MK2452; Tapros|||Taflotan; Tafluprost [DCI]; TAFLUPROST [MI]; TAFLUPROST [JAN]; TAFLUPROST [USAN]; TAFLUPROST [VANDF]; TAFLUPROST [MART.]; TAFLUPROST [WHO-DD]; UNII-1O6WQ6T7G3; Tafluprost (JAN/USAN/INN); Tafluprost [USAN:INN:BAN]; GTPL7451; SCHEMBL1286148; CHEMBL1963683; TAFLUPROST [ORANGE BOOK]; EX-A564; HMS3649F04; HY-B0600; MSK15027; DE-085; DE-118; s4851; AKOS025294885; CCG-269257; DB08819; AS-75193; FT103897; SY338882; NS00001192; D06274; 860T877; EN300-21680961; SR-01000946707; Q2139543; SR-01000946707-1; Z2568721846; (5Z)-7-[(1R,2R,3R,5S)-2-[(1E)-3,3-Difluoro-4-phenoxy-1-buten-1-yl]-3,5-dihydroxycyclopentyl]-5-heptenoic acid 1-methylethyl ester; 7-((1R,2R,3R,5S)-2-((E)-3,3-difluoro-4-fenoxibut-1-en-1-il)-3,5-di-hidroxiciclopentilo)hept-5-enoato de (Z)-isopropilo; 7-((1R,2R,3R,5S)-2-((E)-3,3-difluoro-4-fenoxibut-1-en-1-il)-3,5-di-hidroxiciclopentil)hept-5-enoato de (Z)-isopropilo; (5Z)-7-((1R,2R, 3R,5S)-2-((1E)-3,3-difluoro-4-fenoxi-1-butenil-3,5-di-hidroxiciclopentil)-5-heptenoato de 1-metiletilo (5Z)-7-{(1R,2R,3R,5S)-2-((1E)-3,3-difluoro-4-fenoxibut-1-enil)-3,5-di-hidroxiciclopentil}hept-5-enoato de 1-metiletilo; Ácido 5-heptenóico, éster 7-((1R,2R,3R,5S)-2-((1E)-3,3-difluoro-4-fenoxi-1-buten-1-il)-3,5-di-hidroxiciclopenílico)-, 1-metiletilo, (5Z)-; Ácido 5-heptenóico, éster de 7-[(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-fenoxi-1-butenil]-3,5-di-hidroxiciclopentilo]-, 1-metiletilo, (5Z)-; (Z)-7-[(1R,2R,3R,5S)-2-[(E)-3,3-Difluoro-4-fenoxi-1-buten-1-il]-3,5-di-hidroxiciclopentil]-5-heptenoato de isopropilo; éster isopropílico de tafluprost; D04LCQ; tafluprost solução oftálmica; WSNODXPBBALQOF-VEJSHDCNSA-N; ZINC13912394; ACN-041400; AN-5815; CID9868491; CS-2817; CS-O-11166; RP17751; FT-0701306; X2642; A815061; B0084-087316; AFP-168, AFP-168, AFP-168, MK-2452, MK2452, MK 2452, Taflotan; 1-Methylethyl (5-Z)-7-[(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-phenoxy-1-buten-1-yl]-3,5-dihydroxycyclopentyl]-5-heptenoate; Ácido 5-heptenóico, éster 7-[(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-fenoxi-1-buten-1-il]-3,5-di-hidroxiciclopentil]-, 1-metiletilo, (5Z)-; Ácido 5-heptenóico, éster de 7-[(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-fenoxi-1-butenil]-3,5-di-hidroxiciclopentilo]-, 1-metiletilo, (5Z)- (9CI); AFP 168; MK 2452; Saflutan; Taflotan; Tafluprost; Tapros; (Z)-7-((1R,2R,3R,5S)-2-((E)-3,3-difluoro-4-fenoxibut-1-en-1-il)-3,5-di-hidroxiciclopentil)hept-5-enoato de isopropilo